Circle Pharma, Inc., a South San Francisco, CA-based developer of macrocycle drug discover platform, has extended its seed funding round with an investment from ShangPharma Investment Group Limited.
The amount of the increase, which added to 2014 funding from Pfizer and Mission Bay Capital, was not disclosed. The new investor, ShangPharma Investment Group Limited, is part of the ShangPharma Group, which includes the full service CRO ChemPartner. Circle will work with ChemPartner to build physical libraries of conformationally diverse, cell permeable macrocycles which Circle will integrate into its macrocycle drug development platform.
Founded by computational chemist Prof. Matthew Jacobson (UC San Francisco) and peptide chemist Prof. Scott Lokey (UC Santa Cruz) and led by David J. Earp, J.D., Ph.D., President and CEO, Circle Pharma is developing new discovery technology that facilitates the design and synthesis of intrinsically cell-permeable macrocycles that can address both intra- and extra-cellular therapeutic targets, and can be delivered by oral administration.
Circle’s macrocycle development platform is applicable across a wide range of serious diseases with initial focus on intracellular protein-protein interactions that are key drivers in cancer.